{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:02:21Z","timestamp":1719187341390},"reference-count":64,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2011,1,31]]},"DOI":"10.2217\/fon.10.159","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T16:27:26Z","timestamp":1292948846000},"page":"111-122","source":"Crossref","is-referenced-by-count":3,"title":["Idiotype Vaccine Strategies for Treatment of Follicular Lymphoma"],"prefix":"10.1080","volume":"7","author":[{"given":"Hemchandra","family":"Mahaseth","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE Building B, Suite 4302, Atlanta, GA30322, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D","family":"Brody","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University Medical Center, CA94305, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajni","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE Building B, Suite 4302, Atlanta, GA30322, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pareen J","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE Building B, Suite 4302, Atlanta, GA30322, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE Building B, Suite 4302, Atlanta, GA30322, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,12,21]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2009.1.523.0010523"},{"issue":"19","key":"e_1_3_2_3_3_1","first-page":"5447S","article-title":"An overview of the classification of non-Hodgkin\u2019s lymphomas: an integration of morphological and phenotypical concepts.","volume":"52","author":"Jaffe ES","year":"1992","unstructured":"Jaffe ES , RaffeldM, MedeirosLJ, Stetler-StevensonM: An overview of the classification of non-Hodgkin\u2019s lymphomas: an integration of morphological and phenotypical concepts.Cancer Res.52(Suppl. 19), 5447S\u20135452S (1992).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.10.003"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197404112901501"},{"issue":"6","key":"e_1_3_2_3_6_1","first-page":"2975","article-title":"Nonrandom chromosome abnormalities in lymphoma.","volume":"43","author":"Bloomfield CD","year":"1983","unstructured":"Bloomfield CD , ArthurDC, FrizzeraG, LevineEG, PetersonBA, Gajl-PeczalskaKJ: Nonrandom chromosome abnormalities in lymphoma.Cancer Res.43(6), 2975\u20132984 (1983).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.5.919"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.3322\/CA.2008.0011"},{"issue":"5","key":"e_1_3_2_3_10_1","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas.","volume":"20","author":"Horning SJ","year":"1993","unstructured":"Horning SJ : Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas.Semin. Oncol.20(Suppl. 5), 75\u201388 (1993).","journal-title":"Semin. Oncol."},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"crossref","unstructured":"Schulz H BohliusJ SkoetzNet al.: Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma.Cochrane Database Syst. Rev. (4) CD003805 (2007).","DOI":"10.1002\/14651858.CD003805.pub2"},{"issue":"5","key":"e_1_3_2_3_18_1","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.","volume":"26","author":"Czuczman MS","year":"1999","unstructured":"Czuczman MS : CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.Semin. Oncol.26(5 Suppl. 14), 88\u201396 (1999).","journal-title":"Semin. Oncol."},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1205"},{"issue":"22","key":"e_1_3_2_3_21_1","first-page":"405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany).","volume":"114","author":"Rummel MJ","year":"2009","unstructured":"Rummel MJ , NiederleN, MaschmeyerGet al.: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany).ASH Annual Meeting Abstracts114(22), 405 (2009).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.09.50"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.045"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2717"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2008.09.001"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198203043060906"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.138.4.1289"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.20.10972"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(86)90032-3"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.2.703"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000174040.52427.83"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.3.307"},{"issue":"4","key":"e_1_3_2_3_34_1","first-page":"400","article-title":"Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.","volume":"87","author":"Barrios Y","year":"2002","unstructured":"Barrios Y , CabreraR, YanezRet al.: Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.Haematologica87(4), 400\u2013407 (2002).","journal-title":"Haematologica"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/13928"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.9.3129"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210223271705"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4289"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj358"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj371"},{"key":"e_1_3_2_3_41_1","unstructured":"Timmerman J LevyR CzerwinskiD IngoliaD DenneyDW KunkelL: A Phase II trial to evaluate the efficacy of recombinant idiotype vaccines in untreated follicular non-Hodgkin\u2019s lymphoma in the \u2018watch-and-wait\u2019 period.Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract 13)."},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.18_suppl.2"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8903"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"crossref","unstructured":"Levy R RobertsonM GanjooK LeonardJ VoseJ DenneyD: Results of a Phase III trial evaluating safety and efficacy of specific immunotherapy recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF compared to non-specific immunotherapy KLH with GM-CSF in patients with follicular non-Hodgkin\u2019s lymphoma (fNHL).AACR annual meeting (2008) (Abstract LB-204).","DOI":"10.1158\/1538-7445.AM2008-LB-204"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802563355"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.7529"},{"key":"e_1_3_2_3_47_1","first-page":"2567","article-title":"Active Immunotherapy with mitumprotimut-T (FavId\u00ae, Id-KLH) following rituximab induction in patients (pts) with follicular B-cell lymphoma (FL): progression free survival (PFS) at 4-year follow up.","volume":"110","author":"Koc O","year":"2007","unstructured":"Koc O , RedfernC, WiernikPet al.: Active Immunotherapy with mitumprotimut-T (FavId\u00ae, Id-KLH) following rituximab induction in patients (pts) with follicular B-cell lymphoma (FL): progression free survival (PFS) at 4-year follow up.Blood (ASH Annual Meeting Abstracts)110, 2567 (2007).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3427","key":"e_1_3_2_3_48_1","article-title":"Continued late conversion to complete remission (CR\/CRu) and durability of remission (DUR) in pts with B-cell follicular lymphoma (FL) treated with rituximab followed by mitumprotimut-T (Id-KLH, FavId\u00ae) active immunotherapy.","volume":"110","author":"Koc ON","year":"2007","unstructured":"Koc ON , RedfernC, WiernikPHet al.: Continued late conversion to complete remission (CR\/CRu) and durability of remission (DUR) in pts with B-cell follicular lymphoma (FL) treated with rituximab followed by mitumprotimut-T (Id-KLH, FavId\u00ae) active immunotherapy.Blood (ASH Annual Meeting Abstracts)110(3427), (2007).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488706775246120"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.8.1.43"},{"issue":"4","key":"e_1_3_2_3_52_1","first-page":"479","article-title":"Assessment of platelet antibody by flow cytometric and ELISA techniques: a comparison study.","volume":"116","author":"Lin RY","year":"1990","unstructured":"Lin RY , LevinM, NygrenEN, NormanA, LorenzanaFG: Assessment of platelet antibody by flow cytometric and ELISA techniques: a comparison study.J. Lab. Clin. Med.116(4), 479\u2013486 (1990).","journal-title":"J. Lab. Clin. Med."},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.5.755"},{"issue":"15","key":"e_1_3_2_3_54_1","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.","volume":"28","author":"Salles GA","year":"2010","unstructured":"Salles GA , SeymourJF, FeugierPet al.: Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.J. Clin. Oncol. 2010 ASCO Annual Meeting Proceedings28(S15),(2010) (Abstract 8004).","journal-title":"J. Clin. Oncol. 2010 ASCO Annual Meeting Proceedings"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.4131"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1517"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1974"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.031"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11669219"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq256"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803636105"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-030593"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1071"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.10.159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:27Z","timestamp":1719125007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.10.159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,21]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1,31]]}},"alternative-id":["10.2217\/fon.10.159"],"URL":"https:\/\/doi.org\/10.2217\/fon.10.159","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,21]]}}}